



Charlie Crist
Governor

Ana M. Viamonte Ros, M.D., M.P.H.
State Surgeon General

Florida Vaccines for Children (VFC) Program

IMPORTANT MESSAGE

Important: Prevnar 13 is now available

Dear VFC Program Participants:

The Bureau of Immunization is pleased to bring to your attention an important article published by the Centers for Disease Control and Prevention on March 12, 2010, in the *Morbidity and Mortality Weekly Report* (MMWR Weekly / Vol. 59 / No. 9). This article, *Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children — Advisory Committee on Immunization Practices (ACIP), 2010* (page 258), describes the recommendations and use of an important vaccine in the healthcare provider's disease prevention plan.

This article can be found online at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm>. Please be sure to check <http://www.cdc.gov/mmwr/> for published updates and errata.

On February 24, 2010, a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneumococcal disease (IPD) caused by the 13 pneumococcal serotypes covered by the vaccine and for prevention of otitis media caused by serotypes in the 7-valent pneumococcal conjugate vaccine formulation (PCV7 [Prevnar, Wyeth]). PCV13 is approved for use among children aged 6 weeks-71 months and succeeds PCV7, which was licensed by FDA in 2000. The Pneumococcal Vaccines Work Group of the Advisory Committee on Immunization Practices (ACIP) reviewed available data on the immunogenicity, safety, and cost-effectiveness of PCV13, and on estimates of the vaccine-preventable pneumococcal disease burden. The working group then presented policy options for consideration of the full ACIP.

VFC BLAST FAX 03/18/10 * VFC BLAST FAX 03/18/10

This report summarizes recommendations approved by ACIP on February 24, 2010, for

- (1) routine vaccination of all children aged 2-59 months with PCV13,
- (2) vaccination with PCV13 of children aged 60-71 months with underlying medical conditions that increase their risk for pneumococcal disease or complications, and
- (3) PCV13 vaccination of children who previously received 1 or more doses of PCV7.

CDC guidance for vaccination providers regarding transition from PCV7 to the PCV13 immunization program also is included.

PCV13 is available for ordering through the Vaccines for Children (VFC) Program on March 18, 2010.

Prevnar 13 Ordering Instructions:

VFC Program providers who have a regularly-scheduled order in April 2010:

Place an order as you normally do on the Vaccine Report Form. Prevnar 13 will be shipped with your order. Please follow instructions below for disposal of your Prevnar 7 inventory.

VFC Program providers who do not have a regularly-scheduled order in April 2010:

Complete the ordering section of the attached *Prevnar 13 Order Form and Prevnar 7 Return Form* to place an order for Prevnar 13. Please follow instructions below for disposal of your Prevnar 7 inventory.

Prevnar 7 Disposal Instructions:

Return unused Prevnar 7 as soon as possible after receipt of Prevnar 13 to McKesson Specialty by completing the steps listed below:

- Place Prevnar 7 inventory in the box that Prevnar 13 arrived in.
- Ship Prevnar 7 separately from other expired/wasted vaccine you may have.
- It does not need to be shipped as viable vaccine.
- Complete the returning Prevnar 7 section of the attached *Prevnar 13 Vaccine Order Form and Prevnar 7 Return Form* and include a copy in the box and fax a copy to the VFC Program at (850) 245-4734.
- Two shipping labels will be sent within two weeks of your Prevnar 13 order. Once you receive the labels, call your local UPS office to schedule a pick up.

Only publicly purchased vaccine can be returned to McKesson Specialty. Privately purchased vaccine will be returned to Pfizer directly. Please note that Prevnar vaccine has different lot numbers for public and private orders.

VFC BLAST FAX 03/18/10 * VFC BLAST FAX 03/18/10



Charlie Crist
Governor

Ana M. Viamonte Ros, M.D., M.P.H.
State Surgeon General

Vaccines for Children (VFC) Program Pevnar 13 Vaccine Order Form and Pevnar 7 Return Form

PIN Number:	
Provider Name:	
Shipping Address:	
Telephone Number:	
Contact Person:	

Providers who have a regularly-scheduled order in April 2010:
Place an order as you normally do on the Vaccine Report Form. Pevnar 13 will be shipped with your order. Complete the return section below for any Pevnar 7 inventory you need to return.

Providers who do not have a regularly-scheduled order for April 2010.
Use this form to request your first Pevnar 13 vaccine order. Providers should submit their subsequent Pevnar vaccine request using the latest copy of the Vaccine Report Form.

For VFC Use Only Doses Approved	Name of the Vaccine	Packaging/ Presentation	Number of Doses Requested
	Pevnar 13 – pneumococcal conjugate vaccine	10 pack – Single-dose syringes	

***NOTE:** The VFC Program will make every effort to accommodate your request, given the availability of the vaccine.

For all Providers returning Pevnar 7 vaccine.

For VFC Use Only VACMAN entry	Name of the Vaccine	Packaging/ Presentation	NDC	Expiration Date	Number of Doses Returned
	Pevnar 7 – pneumococcal conjugate vaccine	10 pack – Single-dose syringes	00005-1970-50		

VFC Contact Information:

Telephone: (800) 483-2543; Fax: (850) 245-4734
 Email: FloridaVFC@doh.state.fl.us
 Website: <http://www.ImmunizeFlorida.org/vfc/index.html>